BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc.

  • About
    • Overview
    • Management Team
    • Board of Directors
    • Strategic Advisors
  • Product Pipeline
    • Overview
    • Expanded Access
  • News & Media
    • Press Releases
    • Publications
    • Events
    • Media
  • Investors
    • Investor Relations
    • Overview
    • News / Events
    • Overview
    • Press Releases
    • Press Coverage
    • IR Calendar
    • Email Alerts
    • Company Info
    • Overview
    • Presentations
    • Management Team
    • Contacts
    • FAQ
    • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Business Development
  • Careers
    • Overview
    • Job Openings
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Publications
  • Events
  • Media

BioXcel Therapeutics Announces Pricing of Initial Public Offering

Mar 8, 2018

BioXcel Therapeutics Files Registration Statement for Proposed Initial Public Offering

Feb 13, 2018

New Research Collaboration Between BioXcel Therapeutics and Nektar to Evaluate BXCL701 in Combination with NKTR-214 in Multiple Oncology Indications

Nov 13, 2017

BioXcel Therapeutics to Present Data on [BXCL701] at the 24th Annual Prostate Cancer Foundation Scientific Retreat

Oct 5, 2017

InveniAI Is Launched with Industry-leading Artificial Intelligence (AI) Powered R&D Engine for Biotech and Pharma Partners

May 16, 2017

BioXcel Therapeutics, Inc. (BTI) Is Launched with Phase 2-ready Programs Addressing Unmet Needs in Immuno-oncology and Neuroscience

May 10, 2017

BioXcel Presents Promising Data Demonstrating BXCL701 / Anti-PD1 Combination Increases Anti-Tumor Cytokines and Tumor Growth Inhibition at 2017 AACR Annual Meeting

Apr 3, 2017

UPDATE -- BioXcel Appoints Eric K. Rowinsky, M.D. to its Board of Directors

Jan 5, 2017

BioXcel Appoints Eric K. Rowinsky, M.D. to its Board of Directors

Jan 5, 2017

BioXcel and Centrexion Therapeutics Further Advance Big Data Innovation Lab Collaboration in Chronic Pain

Oct 19, 2016
    • 1...
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    © 2021 BioXcel Therapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap